Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level

References

• CurranMP, PerryCM. Spotlight on amisulpride in schizophrenia. CNS Drugs. 2002;16(3):207–211. doi:10.2165/00023210-200216030-0000711888341
   PubMed Web of Science ®Google Scholar
• LeuchtS, CiprianiA, SpineliL, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/S0140-6736(13)60733-323810019
   PubMed Web of Science ®Google Scholar
• MauriMC, VolonteriLS, ColasantiA, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46(5):359–388. doi:10.2165/00003088-200746050-0000117465637
   PubMed Web of Science ®Google Scholar
• HiemkeC, BergemannN, ClementHW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–2):e1. doi:10.1055/s-0037-160099129390205
   PubMed Web of Science ®Google Scholar
• LiL, LiL, ShangDW, et al. A systematic review and combined meta-analysis of concentration of oral amisulpride. Br J Clin Pharmacol. 2020;86(4):668–678. doi:10.1111/bcp.1424632090363
   PubMed Web of Science ®Google Scholar
• RosenzweigP, CanalM, PatatA, et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17(1):1–13. doi:10.1002/hup.32012404702
   PubMed Web of Science ®Google Scholar
• BergemannN, KopitzJ, KressKR, et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2004;14(3):245–250. doi:10.1016/j.euroneuro.2003.09.00115056484
   PubMed Web of Science ®Google Scholar
• Dos Santos PereiraJN, TadjerpishehS, Abu AbedM, et al. The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J. 2014;16(6):1247–1258. doi:10.1208/s12248-014-9649-925155823
   PubMed Web of Science ®Google Scholar
• KiangTK, SherwinCM, SpigarelliMG, et al. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin Pharmacokinet. 2012;51(8):515–525. doi:10.1007/BF03261928
   Web of Science ®Google Scholar
• ShengL, QuY, YanJ, et al. Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects. Acta Pharmacol Sin. 2016;37(7):994–1001. doi:10.1038/aps.2016.2427180987
   PubMed Web of Science ®Google Scholar
• GlatardA, GuidiM, DelacrétazA, et al. Amisulpride: real-world evidence of dose adaptation and effect on prolactin concentrations and body weight gain by pharmacokinetic/pharmacodynamic analyses. Clin Pharmacokinet. 2020;59(3):371–382. doi:10.1007/s40262-019-00821-w31552612
   PubMed Web of Science ®Google Scholar
• ReevesS, BertrandJ, D’AntonioF, et al. A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease. Psychopharmacology(Berl). 2016;233(18):3371–3381. doi:10.1007/s00213-016-4379-627481049
   PubMed Web of Science ®Google Scholar
• WangZZ, JiaNX, YangLH, et al. Research on therapeutic drug monitoring and clinical application of amisulpride tablets. Chinese J Clin Pharmacol. 2018;34:2704–2706.
   Google Scholar
• MüllerMJ, EichFX, RegenbogenB, et al. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol. 2009;23(3):278–286. doi:10.1177/026988110808980618562411
   PubMed Web of Science ®Google Scholar
• ReevesS, BertrandJ, McLachlanE, et al. A population approach to guide amisulpride dose adjustments in older patients with Alzheimer’s disease. J Clin Psychiatry. 2017;78(7):e844–e851. doi:10.4088/JCP.16m1121628858444
   PubMed Web of Science ®Google Scholar
• McLeaySC, MorrishGA, KirkpatrickCM, et al. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319–330. doi:10.2165/11598930-000000000-0000022439649
   PubMed Web of Science ®Google Scholar
• CockcroftDW, GaultMH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/0001805801244564
   PubMed Web of Science ®Google Scholar
• JönssonAK, SpigsetO, ReisM. A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit. 2019;41(3):348–356. doi:10.1097/FTD.000000000000058531025986
   PubMed Web of Science ®Google Scholar
• BowskillSV, PatelMX, HandleySA, et al. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002–2010. Hum Psychopharmacol. 2012;27(5):507–513. doi:10.1002/hup.225622996618
   PubMed Web of Science ®Google Scholar
• WangST, LiY. Development of a UPLC-MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients. Biomed Chromatogr. 2017;31:8. doi:10.1002/bmc.3928
   Web of Science ®Google Scholar
• SchoretsanitisG, PaulzenM, UntereckerS, et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry. 2018;19(3):162–174. doi:10.1080/15622975.2018.143959529493375
   PubMed Web of Science ®Google Scholar
• XuYJ, WangY, LuYF, et al. Age-associated differences in transporter gene expression in kidneys of male rats. Mol Med Rep. 2017;15(1):474–482. doi:10.3892/mmr.2016.597027909713
   PubMed Web of Science ®Google Scholar
• IvanyukA, LivioF, BiollazJ, et al. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825–892.28210973
   PubMed Web of Science ®Google Scholar
• SchmittU, Abou El-ElaA, GuoLJ, et al. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm. 2006;113(7):787–801. doi:10.1007/s00702-005-0367-416252067
   PubMed Web of Science ®Google Scholar
• MüllerMJ, RegenbogenB, HärtterS, et al. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res. 2007;41(8):673–679. doi:10.1016/j.jpsychires.2005.10.00316324716
   PubMed Web of Science ®Google Scholar
• LindenM, ScheelT, Xaver EichF. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Hum Psychopharmacol. 2004;19(2):111–119. doi:10.1002/hup.57414994321
   PubMed Web of Science ®Google Scholar